Allianz Asset Management
FATE icon

Allianz Asset Management’s Fate Therapeutics FATE Stock Holding History

Allianz Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-24,918
Closed -$617K – 1967
2022
Q2 		$617K Sell
24,918
-30,806
-55% -$850K ﹤0.01% 1840
2022
Q1 		$2.16M Buy
55,724
+1,255
+2% +$48.6K ﹤0.01% 1566
2021
Q4 		$3.2M Buy
54,469
+22,945
+73% +$1.3M ﹤0.01% 1418
2021
Q3 		$1.87M Buy
31,524
+1,111
+4% +$87.1K ﹤0.01% 1676
2021
Q2 		$2.64M Sell
30,413
-14,231
-32% -$1.15M ﹤0.01% 1377
2021
Q1 		$3.68M Sell
44,644
-964
-2% -$92.4K ﹤0.01% 1181
2020
Q4 		$4.15M Buy
+45,608
New +$2.83M ﹤0.01% 1105
2020
Q2 		– Sell
-31,670
Closed -$703K – 2434
2020
Q1 		$703K Sell
31,670
-12,931
-29% -$327K ﹤0.01% 1928
2019
Q4 		$873K Buy
44,601
+654
+1% +$10.4K ﹤0.01% 2253
2019
Q3 		$682K Sell
43,947
-64,619
-60% -$1.24M ﹤0.01% 2267
2019
Q2 		$2.2M Sell
108,566
-983
-0.9% -$17.7K ﹤0.01% 1847
2019
Q1 		$1.93M Buy
109,549
+1,188
+1% +$18.8K ﹤0.01% 1847
2018
Q4 		$1.39M Buy
108,361
+229
+0.2% +$3.19K ﹤0.01% 1897
2018
Q3 		$1.76M Buy
+108,132
New +$1.28M ﹤0.01% 1991
2016
Q3 		– Sell
-18,252
Closed -$31K – 2592
2016
Q2 		$31K Sell
18,252
-179,077
-91% -$325K ﹤0.01% 2542
2016
Q1 		$355K Sell
197,329
-11,978
-6% -$24.7K ﹤0.01% 2319
2015
Q4 		$705K Buy
209,307
+16,711
+9% +$70.2K ﹤0.01% 2108
2015
Q3 		$1.03M Buy
+192,596
New +$1.32M ﹤0.01% 1818

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Allianz Asset Management's FATE Position: Q3 2022 in Review

Allianz Asset Management sold out of Fate Therapeutics (FATE) in Q3 2022, closing a stake of 24,918 shares — an estimated $617K sold.

Allianz Asset Management first reported a position in FATE in Q3 2015 and held it in 18 quarters. The position peaked at $4.15M in Q4 2020. 239 funds tracked by Wall St. Rank hold FATE as of Q3 2022.

  • Allianz Asset Management reported no remaining Fate Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Allianz Asset Management sold 24,918 Fate Therapeutics shares in Q3 2022, an estimated $617K.
  • Allianz Asset Management first reported a position in Fate Therapeutics in Q3 2015 and held it in 18 quarters.
  • Allianz Asset Management's Fate Therapeutics position peaked at $4.15M in Q4 2020.
  • 239 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2022.

Based on Allianz Asset Management's 13F filing for Q3 2022, filed 8 Nov 2022.